Company to Showcase data generated from its novel Microscoop® platform, including biomarker discovery showcasing multiple novel stress proteins
WASHINGTON DC – DECEMBER 3, 2022 – Syncell Inc., a life science company revolutionizing spatial biology research, will present at Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), showcasing its new spatial proteomics data. Using its innovative spatial proteomics system, Microscoop®, Syncell has generated groundbreaking cell biology-related biomarker discovery data. At Cell Bio 2022, the data will be categorized and presented at different sessions throughout the week in four posters. One poster that stands out in particular shows multiple novel stress granule proteins identified by Microscoop®. Verified with immunostaining, the novel stress granule proteins offer high-impact data.
The Microscoop® platform is an integrated optoproteomics platform for protein mapping. It is the first and only system that allows users to pick up and identify thousands of known and unknown proteins in specified cellular and subcellular locations. Researchers using Microscoop® can identify novel proteins to deduce new molecular mechanisms for novel biomarkers for diagnosis and drug discovery.
Microscoop® doesn’t require using a predefined antibody panel to explore morphology-based protein expression. The system uses an AI or traditional computer vision program to recognize the target cells or organelles and then applies proximity photolabeling to tag the proteins accurately in the target areas with biotin. After photolabeling, the biotinylated proteins are extracted from the samples and subjected to mass spectrometry proteome analysis.
“We’re excited to share the latest biomarker data, highlighting discoveries that are key to understanding neurodegenerative and other diseases and improving patient treatments and outcomes. This granule protein data is especially of interest and relevant for researchers who want to study proteomics of very small organelles,” said Dr. Jung-Chi Liao, Ph.D., founder and CEO of Syncell. “Microscoop® has overcome the technical limitations of existing bioimage-based spatial proteomics tools that rely solely on using antibody panels to study known proteins.”
Poster Session and Booth Details:
【Poster Session #1】
- Day/Date of Presentation: Sunday Dec 4, 2022
- Poster Session Title: Poster Session: Imaging Technologies, Single Molecule Imaging, and Super-resolution
- Poster Board Number: B37
- Time and Place: 12:15-1:45 PM, Exhibit Hall AB
【Poster Session #2】
- Day/Date of Presentation: Monday, December 5, 2022
- Poster Session Title: Poster Session: Proteomics and Genomic Methods
- Poster Board Number: B37
- Time and Place: 12:15-1:45 PM, Exhibit Hall AB
【Poster Board #3】
- Day/Date of Presentation: Monday Dec 5, 2022
- Poster Session Title: Poster Session: Neuronal Degeneration and Regeneration
- Poster Board Number: B405
- Time and Place: 12:15-1:45 PM, Exhibit Hall AB
【Poster Session #4】
- Day/Date of Presentation: Tuesday, December 6, 2022
- Poster Session Title: Poster Session: Stress Response, Chaperones and Quality Control
- Board Number: B571
- Time and Place: 12:15-1:45 PM, Exhibit Hall AB
- Booth Number: 1609
About Syncell
Syncell is a commercial stage life science instrument company, with a vision to revolutionize spatial biology research. Its first product, Microscoop®, is the first and only microscopic bioimaging system that allows researchers to pick up, identify and quantify thousands of known and unknown proteins in specified cellular and subcellular locations. Syncell currently offers global customers early access to Microscoop® technology through its custom service program GRASP (Global Rapid Access Service Program). Microscoop® will provide deep spatial proteomics insights to transform a wide range of basic biology and translational research including neuroscience, oncology, immunology, or infectious disease to identify novel biomarkers with spatial context to accelerate biomarker discovery research and drug development programs.
